Now Dipensing ENHERTU®

Onco360 is privileged to be selected as a specialty pharmacy provider for Daiichi Sankyo’s product, ENHERTU^® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER-2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Breast cancer is the second most common cancer in American women. The American Cancer Society estimates over 300,000 new cases for breast cancer in the United States in 2020. HER2-positive cancers occur when breast cancer cells with higher than normal levels of HER2 (a growth promoting protein on the outside of all breast cells) develop. These cancers tend to grow and spread faster than other breast cancers but are more likely to respond to treatments that target the HER2 protein, such as ENHERTU.

ENHERTU gained accelerated FDA approval based on the DESTINY-BREAST01 trial that showed clinically meaningful and durable response rates. The results of ENHERTU monotherapy demonstrated a response rate of 60.3%, including a 4.3% complete response rate and a 56.0% partial response rate.

ENHERTU is available for injection as 100 mg lyophilized powder in a single-dose vial and manufactured by Daiichi Sankyo, Inc. It was approved by the FDA on December 23, 2019. See full prescribing information.

ENHERTU is now available to order through Onco360.